Regulation of growth factors in hormone‐ and drug‐resistant prostate cancer cells by synergistic combination of docetaxel and octreotide

Abstract

caspase 3/7 activity were measured. We also investigated the effect of combined docetaxel and octreotide on growth factors secreted from prostate cancer cells using a human growth factor antibody array. RESULTSThe combination of docetaxel and octreotide resulted in significant synergistic cytotoxic activity and apoptosis, which was dose-and time-dependent. The combined treatment also resulted in significantly less secretion of stem cell factor and platelet-derived growth factor-AB in PC-3 cells, and transforming growth factor-β and basic fibroblast growth factor in DU-145 cells, than in untreated controls. CONCLUSIONOctreotide, a somatostatin analogue, combined with docetaxel might provide a rationale treatment option for hormonerefractory prostate cancer cells, not only by direct inhibition of cell proliferation but also by inhibiting the secretion of growth factors.

Differential molecular mechanism of docetaxel–octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells

“…PC3wt cells treated with the sequential schedule were more sensitive to cell death if docetaxel was given before octreotide, compared with docetaxel alone. This observation was similar to that obtained by Erten et al [27] showing a significant synergistic effect of the sequential treatment irrespective of which agent was given first. For PC3R cells, the stronger effect on cell proliferation was observed when the two drugs were given together 4 days after seeding.…”

“…These results are also in agreement with data on hepatocellular carcinoma cell lines [26]. Our data are, however, not in agreement with the results obtained in prostate cancer cell lines by Erten et al [27], who reported that both docetaxel and octreotide decreased cell proliferation in a time-dependent and dose-dependent manner when using PC3wt and DU145 cells, indicating different roles of the two drugs on those cell lines.…”

Modulation of Postoperative Scarring with Tacrolimus and Octreotide in Experimental Glaucoma Filtration Surgery

“…28 In another study, the combination of Docetaxel and Octreotide significantly reduced the levels of FGF-β in human hormone and drug refractory prostate cancer cell lines. 29 In present study MMC, Octreotid and Tacrolimus equally decreased the FGF-β immunostaining intensity at the scleral flap region.…”

Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels

“…The relative amounts of mono and oligonucleosomes generated from the apoptotic cells were quantified using monoclonal antibodies directed against DNA and histones by ELISA. Detection of apoptosis was verified by measuring caspase 3/7 enzyme activity as described in our previous study (Erten et al 2009). It is of note to mention that caspase 3/7 enzyme activity was only measured in MDA-MB-231, since MCF-7 lack of caspase 3 enzyme.…”